Ipsen Biopharmaceuticals, Inc.
Records under this name other than the patents Ipsen Biopharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 5 of 5 · Back to Ipsen Biopharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,258,864 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency Term ended Term ended Aug 26, 2025 · USPTO record | Term ended | Term ended Aug 26, 2025 | USPTO record |
| US 8,133,862 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency Term ended Term ended Mar 31, 2025 · USPTO record | Term ended | Term ended Mar 31, 2025 | USPTO record |
| US 7,517,530 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency comprising administration of IGF-1 and growth hormone Term ended Ended no later than Sep 9, 2024 · USPTO record | Term ended | Ended no later than Sep 9, 2024 | USPTO record |
| US 8,158,582 | Methods for treatment of insulin-like growth factor-1 deficiency Lapsed on the fee record Ended Apr 17, 2024 · USPTO record | Lapsed on the fee record | Ended Apr 17, 2024 | USPTO record |
| US 8,440,616 | Methods for treatment of insulin-like growth factor-1 deficiency Lapsed on the fee record Ended May 14, 2021 · USPTO record | Lapsed on the fee record | Ended May 14, 2021 | USPTO record |